؉ cells is an important objective for gene therapy of AIDS, as these cells represent the principal target for viral replication of human immunodeficiency virus (HIV). We report here that specific combinations of CD4 cell-specific and viral regulatory elements can enhance expression of an antiviral gene product. Different viral regulatory elements were incorporated into a previously reported CD4 locus control region to increase the expression of reporter genes in T and monocytic cell lines. The CD4-specific regulatory elements were included to enhance expression in CD4 cells, and viral regulatory regions, including the cytomegalovirus immediate-early (CMV IE) upstream enhancer, which contains the B and Ap1 regulatory elements and a Tat-responsive element of the HIV type 1 long terminal repeat, were used to increase gene expression and modulate its activity in response to viral infection. In transient transfection assays, this vector was 100-to 1,000-fold more active than the original CD4 regulatory elements alone. Expression of an inhibitory form of the Rev protein, Rev M10, was more effective than previously described vectors and protected against productive viral replication in CD4
The problems encountered in devising effective treatments for AIDS have emphasized the need to develop alternative strategies to treat this condition. One such approach is the transfer of genes which inhibit productive replication of human immunodeficiency virus (HIV) in its target cells. A genetic intervention strategy against HIV requires the identification of one or more gene products that are able to inhibit or restrict the replication of HIV. It is also important to regulate antiviral gene expression and minimize any adverse effects on normal cellular gene expression. A number of antiviral genes have been successfully identified in cell culture models. These include Tat activation response (TAR) element and Rev response element (RRE) decoys (1, 5, 31, 34, 63) , ribozymes (47, 55, 71, 73) , toxic gene products (10, 13, 24) , intracellular antibodies (15, 41, 43) , antisense genes (67) , and transdominant negative mutants of HIV structural (65) and regulatory (2, 4, 33, 38, 44, 48, 67) proteins. The Rev regulatory protein of HIV offers some attractive features that make it a viable candidate for genetic strategies. The expression of functional Rev is essential for the translocation of unspliced or singly spliced HIV mRNA from the nucleus to cytoplasm (18, 39, 60) . More importantly, the presence of Rev above a threshold level is critical for its biological function (49) . Rev M10, a transdominant negative mutant of Rev (36, 40) , has been shown to effectively block the function of wild-type Rev in T cells and peripheral blood mononuclear cells (PBMC) (2, 4, 35, 38, 68) .
Another factor which is likely to affect the success of gene transfer strategies is the ability to express sufficient amounts of inhibitory gene products in the relevant cell type. Although the PBMC represents a relevant target cell of HIV infection, transfer of genes into PBMC by using viral vectors has become increasingly efficient but requires stimulation of cells for optimal gene transfer. This process also activates latent provirus in these cells (23, 72) , but techniques have recently been used successfully to deliver antiviral genes without activating endogenous HIV replication in vitro (19, 46) . At least one nonviral vector, using particle-mediated gene transfer, has also been shown to provide effective gene transfer, improve safety, and confer antiviral effects (70) . Monocytic cells are also readily infected by the virus, and for this reason, efforts have been made to express such genes in hematopoietic stem cells and early progenitors. Protocols for identification and isolation of the stem cells and the introduction of recombinant genes have been developed (29, 62) . Independent of the method of gene transfer or the intended target cell population, cell-specific and regulated expression of the introduced genes is desirable for gene transfer strategies in AIDS. Most previous studies have made use of retroviral regulatory elements, such as those found in Moloney murine leukemia virus or Rous sarcoma virus (RSV), for this purpose. These regulatory elements do not confer cell-specific expression and are weakly active in PBMC. In addition, the expression pattern of these promoters varies among different cell types (52) . CD4, the principal cellular receptor for HIV (14) , plays an important role in HIV infection and pathogenesis (64) , is down-regulated on the cell surface following infection with this virus (25) , and serves as a marker for the cell lineages which diminish progressively over the course of HIV infection (7) . Several subsets of macrophages or dendritic cells which are believed to function as the reservoirs of HIV are also positive for CD4 expression (17) . For these reasons, CD4
ϩ T cells and macrophages or dendritic cells represent logical targets for anti-HIV gene therapy. A 339-bp regulatory element which controls CD4-restricted gene expression of reporter genes has been identified approximately 13 kb upstream of the murine CD4 promoter (56) . When this regulatory element was placed upstream of the CD4 promoter, expression was restricted to CD4 ϩ cells (56) . The combination of the CD4 enhancer and promoter, however, is relatively weak in T cells, particularly in transiently transfected PBMC. In this study, we report modifications made to this vector that result in enhanced transcriptional activation in PBMC and responsiveness to viral transactivators, such as Tat, as well as cellular activators of HIV gene expression, including NF-B and Ap1. Expression and efficacy of Rev M10 in these vectors were evaluated in an attempt to improve its antiviral effect and maintain expression in CD4 cells.
MATERIALS AND METHODS
Cell culture. All cell lines except HeLa were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum penicillin (100 U/ml), streptomycin (100 g/ml), and glutamine (Gibco BRL, Gaithersburg, Md.). 2-Mercaptoethanol (50 M) was added to the THP-1 cultures. HeLa cells were grown in Dulbecco modified Eagle medium containing 10% fetal calf serum, glutamine, and antibiotics. PBMC were cultured in X-Vivo 15 medium (BioWhittaker, Walkersville, Md.) supplemented with interleukin-2 (IL-2; 300 IU/ml; Cetus). Cells were incubated at 37°C in 5% CO 2 .
Vectors (i) pK7-CAT. The vector pK7-CAT was derived from the parental vector pBL(CD4)-CAT (56) by making two modifications. First, a unique BglII site was created upstream of the XbaI site at the 5Ј end of the CD4 promoter. CD4 promoter fragments were amplified by using a common sense primer, and variable antisense primers containing BglII and XbaI restriction enzyme sites, respectively, replaced the original promoter. This created mutant promoters with progressive deletions at the transcription initiation site. The full version of the amplified promoter lacked the untranslated 70-bp fragment at the 3Ј end of the original promoter. Second, a section of the HIV type 1 (HIV-1) genome (Ϫ80 to ϩ72) consisting of the three Sp1 sites, the TATA box, and TAR was amplified by PCR and cloned downstream of the CD4 promoter. Additional modifications were made to this basic vector, pK7-CAT. The cytomegalovirus (CMV) enhancer element (Ϫ583 to Ϫ224) (6), amplified with primers flanked with SphI sites, was cloned upstream of the CD4 regulatory element to derive pK7c-CAT. The CMV enhancer was also cloned into the parental vector to make the vector pBLc (CD4)-CAT.
(ii) pK7c Rev M10. The expression vector pK7c-Rev M10 was constructed by deleting the RSV promoter and the TAR sequence of the pRSV-TAR-Rev M10 vector by AatII and HindIII digestion. The pK7c cassette (CMV enhancer, CD4 regulatory element, CD4 promoter, and TAR) from pK7c-CAT was removed by HindIII and XhoI digestion and was blunt-end ligated to the backbone described above. The pK7c cassette was thus placed upstream of the Rev M10 gene. The bovine growth hormone poly(A) sequence present in these vectors was replaced by the poly(A) sequence derived from the ␤-globin gene (a BglII-PflMI fragment of 213 bp) (66) . The vectors pRSV-Rev, pRSV-CAT-RRE, pRSV-Rev M10 (35) , HIV-CAT (50), and pHD101 Tat (42) have been described previously.
(iii) pK7cI-Rev M10. The final version of the HIV-1 long terminal repeat (LTR) and the CD4 promoter chimeric vector, pK7cI-Rev M10, was constructed as follows. The HindIII-SalI fragment of the CMV immediate-early (IE) intron was removed from the vector pUCint3Ј and blunt-end ligated into the HindIII site (between TAR and Rev M10) of the vectors pK7c-Rev M10. This version of the CMV IE intron contains an internal deletion between the XcmI and HpaI sites. The control vector pK7cI-⌬Rev M10 was constructed by using the same scheme. This control vector is identical to the expression vector except that there is a 2-bp deletion in the transcription initiation site. An additional control vector, pK7cI-⌬TAR ⌬Rev M10, was constructed by deleting a 30-bp fragment of the TAR region (SacI to AflII) to disrupt the stem-loop structure.
Gene transfer. Suspension cultures were transfected by using a modification of the DEAE-dextran method (22) . Briefly, 5 ϫ 10 6 cells were transfected with 5 to 6 g of total DNA. The DNA concentrations were made up with pBluescript wherever necessary. Cells were washed twice with TS buffer (0.137 mM NaCl, 7 mM KCl, 0.3 mM Na 2 HPO 4 , 0.5 mM MgCl 2 , 0.7 mM CaCl 2 , 25 mM Tris base [pH 7.4]) and resuspended in 475 l of TS buffer containing DNA. DEAEdextran (molecular weight, 500,000; Pharmacia) was added to the cell suspension at a final concentration of 0.5 mg/ml and then incubated for 15 min at room temperature. Five milliliters of RPMI complete medium supplemented with 1 mM chloroquine (Sigma, St. Louis, Mo.) was added to each tube, and the cells were incubated for 30 min at 37°C. The cells were washed once with complete medium and seeded in six-well tissue culture plates. Cells in parallel sets were stimulated with phorbol 12-myristate 13-acetate (PMA; 10 ng/ml) 24 h after transfection and harvested after an additional 24 h of incubation. HeLa cells were transfected by the CaPO 4 method (12) . PBMC were transfected by particlemediated gene transfer as described previously (70) .
Gene expression and viral challenge. Chloramphenicol acetyltransferase (CAT) assays were performed as described previously (59) , with some modifications. Cells were harvested, washed once with phosphate-buffered saline and resuspended in 0.25 M Tris (pH 7.8). They were lysed by three or four cycles of freezing and thawing, and clear lysates were collected after clearing the debris by microcentrifugation. Protein content of the cell extracts was determined by the dye-binding assay (Bio-Rad, Hercules, Calif.). The reaction mixture of 150 l consisted of measured amounts of protein, 20 l of acetyl coenzyme A (3.5 mg/ml in 0.25 M Tris), 2 l of [ 14 C]chloramphenicol, and 0.25 M Tris (pH 7.8). The amount of protein added and the length of incubation at 37°C varied depending on the transcriptional strength of the vectors used. Experiments were repeated several times. The reaction products were extracted with 0.5 ml of ethyl acetate. The organic phase was lyophilized, and the pellets were redissolved in 30 l of ethyl acetate. The samples were spotted on a thin-layer silica gel plate (catalog no. 4410221; Whatman) and run in a glass chamber with 95:5 chloroform-methanol mixture. The chromatograms were analyzed on a ␤-scope. Virus challenge experiments were performed as described previously (70) .
RESULTS

Development of a CD4 promoter which is responsive to Tat.
CD4 lineage-specific expression of a CAT reporter with regulatory elements from the murine CD4 gene was reported previously (56) . A 339-bp regulatory fragment from a region ϳ13 kb upstream of the murine CD4 gene was shown to confer CD4-specific expression of the CAT gene when used in combination with the CD4 promoter; however, this combination of CD4 regulatory elements was 10-to 20-fold less efficient than HIV or RSV promoters used previously to express recombinant genes in T cells (Fig. 1 ). To increase gene expression and maintain the CD4-specific regulatory elements, different combinations of heterologous regulatory regions were analyzed. We first replaced 70 bp of untranslated sequence (at the 3Ј end of the CD4 promoter) with a segment of the HIV-1 LTR consisting of the three Sp1 sites, the TATA box, and the TAR sequence. The presence of the Sp1 sites upstream of TAR is essential for responsiveness to Tat transactivation (3, 58, 61) , as is the presence of TAR at the 5Ј end of the mRNA (26, 45, 58) . Deletion of this 70-bp 5Ј untranslated segment was thus required to make this hybrid promoter responsive to Tat (data not shown). Additional deletions were made at the 3Ј end of the CD4 promoter to map sequences that might be dispensable for transcriptional function with the addition of the HIV promoter. Progressive deletions at the 3Ј end of the CD4 promoter were analyzed when linked to the HIV promoter placed immediately downstream of each of these deletions, and the transcriptional activity of each of these chimeric vectors was estimated in transient transfection assays of Jurkat cells in the presence or absence of Tat. The CD4-Sp1/TAR hybrid vectors were functional in the CAT assay at levels significantly higher than those generated from the parental vector pBL(CD4)-CAT. CAT expression was enhanced 2-to 15-fold in the presence of Tat, indicating that the TAR sequence in these plasmids was functional. The resultant hybrid vector, pK7-CAT, with the full-length CD4 promoter (Ϫ409 to ϩ1), the Sp1 sites, and TAR displayed higher CAT activity than other reporter plasmids. Hybrid vectors containing progressive deletions into the 3Ј end of the promoter demonstrated proportionately decreased CAT activity (Fig. 1) . These results indicated that the full-length CD4 promoter without 5Ј untranslated RNA sequences provided optimal gene expression from the chimeric vector in transient transfections. We also prepared chimeric vectors which lacked the Sp1 sites in the HIV-1 LTR, consisting of only the TATA box and the TAR sequence (Ϫ47 to 72), but these vectors were not Tat responsive in transient transfection assays. In contrast, pK7-CAT was Tat responsive ( Fig.  2A) , confirming the functional importance of the Sp1 and TAR sites (3, 61) in this promoter context. Based on these results, pK7-CAT was selected for further modification.
Addition of the CMV upstream enhancer to the CD4-TAR promoter. A 360-bp CMV enhancer element was placed upstream of the CD4-specific enhancer element in pK7-CAT. This element contains at least six B regulatory elements and an additional Ap1 site. These sites are recognized by NF-B and Fos-Jun, respectively, both of which are stimulated following T-cell activation (21, 28) . The resulting vector, pK7c-CAT, was tested in parallel with pK7-CAT for transcriptional activity in a transient transfection assay (Fig. 2B) . In Jurkat cells, the levels of transcription in the absence of Tat transactivation were 8.6-fold higher when the CMV enhancer was present in the vector than in its absence. Although minimal increase in transcription was seen in unstimulated cells cotransfected with Tat, in most cell lines and in PBMC, the presence of the CMV enhancer in the vector resulted in increased CAT activity both in the presence and in the absence of Tat (see below). Addition of the CMV enhancer to the parental vector pBL(CD4)-CAT, on the other hand, had no effect on transcriptional activity, with CAT activity barely detectable (data not shown).
Expression of the CD4-TAR hybrid promoter in different cell lines. Expression of the parental vector pBL(CD4)-CAT has been previously shown to be T-cell specific, due to the presence of its CD4-specific enhancer and promoter elements. To determine whether the pattern of gene expression of the altered promoter would differ from that of the parent, its expression patterns in T-and non-T-cell lines were analyzed. Transient transfection assays were performed, and cells were stimulated with PMA 24 h later. Cells were incubated for an additional 24 h, and CAT activity was determined. Then the vectors pBL(CD4)-CAT, pK7-CAT, pK7c-CAT, HIV-CAT, and RSV-CAT were compared in two T-cell leukemia lines in the absence or presence of PMA. In Jurkat cells, both pK7-CAT and pK7c-CAT showed enhanced CAT activity in the absence of PMA stimulation, and the level was four-to fivefold higher in the presence of Tat (Fig. 3A) . When the cells were stimulated with PMA, these vectors displayed ϳ3-to 14-foldincreased CAT activity (Fig. 3A) . pK7c-CAT, for example, showed 10.3-and 40-fold-higher CAT activity in the presence of PMA alone and PMA and Tat together, respectively. In H9 cells, pK7c-CAT activity was 15.3-and 108.2-fold higher with PMA stimulation alone and PMA-Tat stimulation, respectively. The parental vector pBL(CD4)-CAT showed less than 0.1 to 0.3% of this CAT activity under the same conditions. Taken together, pK7c-CAT was significantly more active than the parental vector, with 52.3-and 141.5-fold-higher levels of CAT activity upon PMA stimulation and Tat transactivation in Jurkat and H9 cells, respectively.
The transcriptional activity of pK7c-CAT was also determined in non-T cells lines, including THP-1 (monocytic leukemia), U937 (premonocytic lymphoma), JY (B cells), and HeLa (cervical epithelioid carcinoma). The pattern of CAT activity in the presence of PMA (Fig. 4) was essentially the same as in unstimulated cells but was severalfold greater in magnitude (data not shown). The chimeric CD4 vectors were functional in each cell type. pK7c-CAT activity was again greater than pK7-CAT activity in all cells under all experimental conditions. As noted in T cells, Tat transactivation in all of these cells resulted in increased CAT activity in pK7c-CAT, ranging from 6.9-fold (THP-1) to 80.9-fold (JY) to 85.0-fold (U937). CAT expression from the parental vector pBL(CD4)-CAT remained undetectable. With these additions, pK7c-CAT was found to be comparable to HIV-CAT in several cell lines and often more active than the RSV LTR ( Fig. 3 and 4) . In summary, although viral regulatory elements in addition to the CD4 enhancer/promoter resulted in a broader range of cell-specific expression, it provided for enhanced transcriptional activity. Unlike the viral LTRs or the parental CD4 locus control region, the CD4-TAR hybrid promoter displayed higher transcriptional activity in all of the cell lines tested.
Gene expression in CD4 ؉ PBMC. We tested the expression pattern of pK7c-CAT in PBMC, as these cells present a relevant target for anti-HIV gene transfer. Importantly, in the absence of Tat, pK7c-CAT displayed transcriptional activity in PBMC from normal donors that was about 3.4-fold higher than that of RSV-CAT. Under the same conditions, pK7c-CAT demonstrated approximately 75.0-and 4.0-fold-higher CAT activity than HIV-CAT in the absence and presence of Tat (Fig. 5A) . Inclusion of the CMV enhancer rendered this vector significantly more active in PBMC. pK7c-CAT displayed 18.8-and 27.2-fold-higher CAT activity compared to pK7-CAT in the absence and presence of Tat transactivation, respectively. Under the same conditions, the parental vector pBL(CD4)-CAT displayed no detectable CAT activity.
The results of transient transfection assays using PBMC demonstrated that the vector pK7c-CAT was several hundredfold stronger than the parental vector pBL(CD4)-CAT. In an attempt to increase the transcriptional activity of this vector further, a 386-bp subfragment of CMV IE intron A was cloned into pK7c-CAT such that it was placed between the TAR sequence upstream and the CAT gene downstream. This intron has been shown previously to increase expression of the 1-foldstronger activity in the absence and presence of Tat transactivation, respectively. This vector also showed stronger activity than RSV-TAR-CAT, a prototype of the vector used in previous clinical gene transfer studies (69) , especially in the absence of Tat transactivation, in which case it was 36.4-fold higher. Importantly, the CAT activity of pK7cI-CAT was expressed at higher levels than those of the other vectors for longer time periods (Fig. 5B, right panel) . Seventy-two hours after the transfection, pK7cI-CAT showed 10.9-and 9.5-foldhigher CAT activity compared to RSV-TAR-CAT in the absence and presence of Tat transactivation, respectively. CAT activity of the parental vector pBL(CD4)-CAT remained below detection in these experiments (data not shown). Transcription start site in the optimized vector. In in vitro transient transfection assays, the chimeric vector stimulates CAT reporter gene expression effectively. Because transcriptional initiation from this chimeric promoter could theoretically be derived from two major transcription initiation sites, one from each promoter, we performed primer extension analysis on total RNA extracted form PBMC transduced with pK7c-Rev M10 to determine which sites were functional. DNA fragments of 68 or 148 bp were expected depending on whether the transcription initiation site was located in TAR or in the CD4 promoter, respectively. A single band at the 68-bp level was detected in a dose-dependent fashion (Fig. 6, lanes 3  and 4) . No signal was seen with RNA isolated from untransduced PBMC (Fig. 6, lanes 1 and 2) . No other extension product of higher molecular weight was found, indicating that the transcription start site from HIV but not the CD4 promoter is functional in this promoter. Identical results were obtained also in 293 cells transfected with pK7c-CAT, pK7c-Rev M10, or pK7cI-Rev M10 (data not shown).
Rev M10 function in chimeric CD4 expression vectors. These data indicated that the combination of the CD4 and viral regulatory elements in the pK7c-CAT vector significantly increased CAT reporter gene expression. To determine whether this vector could provide improved Rev M10 inhibition of HIV replication, the CAT gene in pK7c-CAT was replaced with the Rev M10 open reading frame to generate the pK7c-Rev M10 vector (Fig. 7A) . The 386-bp CMV intron was subsequently cloned upstream of the Rev M10 gene to make pK7cI-Rev M10. A control vector with a deletion in the translation initiation codon (pK7cI-⌬Rev M10) was analyzed, although another control vector with an additional deletion in the TAR stem-loop (pK7cI-⌬TAR-⌬Rev M10) was tested to control for potential inhibition by the TAR RNA structure which can act as a decoy (63), with similar effects (data not shown). A cotransfection inhibition assay was performed as reported previously (35) to determine whether expression of Rev M10 from these promoters could inhibit Rev-dependent CAT activity. A vector expressing Rev M10 under the regulation of the RSV LTR and HIV TAR (pRSV-TAR-Rev M10) and its identical control vector (pRSV-TAR-⌬Rev M10) were included for comparison. This vector had been used in previous clinical studies (69) . Coexpression of the reporter vector, pRSV-CAT-RRE, with increasing amounts of the transactivating plasmid, pRSV-Rev, resulted in a linear increase in CAT activity (data not shown). To perform the inhibition assay, Jurkat cells were cotransfected with a constant concentration of pRSV-CAT-RRE and pRSV-Rev and increasing amounts of different Rev M10 or control expression plasmids both in the absence and in the presence of a Tat expression vector. Controls were included where the CAT expression vector was transfected in the absence of the Rev expression vector. The conversion levels obtained from such controls were substracted to account for background. These assays revealed that the optimized vector pK7cI-Rev M10 effectively inhibited Revdependent CAT expression in a dose-dependent manner both in the absence and in the presence of Tat expression (Fig. 7A and B, respectively) relative to the controls. In both cases, pK7cI-Rev M10 showed stronger inhibition than pRSV-TARRev M10. The experimental design is complex, as it requires four vectors to enter the same cell to show CAT reporter inhibition. Complete specific CAT inhibition is unlikely under these conditions. To overcome this limitation, we compared the vectors in the linear range of the assay. It is important to compare the vectors in the linear range rather than to look for complete inhibition at higher concentrations where such comparisons are less sensitive. Such a comparison of pK7cI-Rev M10 and pRSV-TAR-Rev M10 showed the former to be an order of magnitude stronger than the latter. For example, approximately 50 ng of the optimized vector was required for half-maximal reduction in CAT conversion in the presence of Tat (Fig. 7B, right panel) . To achieve the same levels of inhibition, 400 ng of the pRSV-TAR-Rev M10 was required under the same conditions.
Protection against virus challenge. The potential of these vectors to inhibit HIV-1 infection in PBMC was examined in virus challenge experiments. Freshly isolated PBMC were cotransduced with one of the Rev M10 or ⌬Rev M10 expression vectors and a CMV-CAT vector by particle-mediated gene transfer. CAT activity was used as a reporter to measure overall cell viability after virus challenge. The cells for each vector were divided into halves; one group was challenged with HIV-1 Bru , while the other served as nonchallenged reference control. CAT activity was quantitated on days 2 and 3. The levels FIG. 5. CD4-TAR hybrid promoter-driven CAT expression in peripheral blood lymphocytes. PBMC were freshly isolated by using Ficoll-Hypaque and stimulated with immobilized anti-CD3 antibody and IL-2 (50 U/ml) for 2.5 days. PBMC derived from different donors were used in these experiments. Cells (10 5 /assay) were transduced by particle-mediated gene transfer with 1 g of CAT expression vector and 0.3 g of pHD101 or pBluescript as described elsewhere (70) . Following gene transfer, the cells were incubated in the presence of the anti-CD3 antibody for 24 h. (A) CAT activity in 20 g of the protein extract was determined in a 5-h incubation at 37°C; (B) 14 g of protein was used, and the reaction mixture was incubated for 1 to 5 h. The reaction conditions were optimized for the strongest vector used in the experiment such that the conversion would not exceed 60 to 70% level. The results are representative of at least four independent experiments, with standard deviation generally Յ10% for each determination in the CAT assay. The values are shown as percent conversion of chloramphenicol to its acetylated derivatives. Values in parentheses represent fold transactivation due to Tat.
of CAT activity in cells transfected with Rev M10 expression vectors as opposed to the controls reflected the protection afforded to the cells by Rev M10. In this analysis, the optimized vector pK7cI-Rev M10 provided effective antiviral protection in these experiments (Fig. 8) . On day 3, no reduction in CAT activity was seen as a result of the viral challenge with the optimized vector, whereas a 5.3-fold reduction was observed in cells transfected with the control vector. Similar results were also observed with pRSV-TAR-Rev M10 and its control vector used previously in clinical studies (2.9-fold reduction), and identical results were observed on day 2 (data not shown). Protection against HIV-1 IIIb infection was also observed in 293 cells constitutively expressing the CD4 receptor (data not shown).
DISCUSSION
Because of its ability to inhibit productive HIV replication in several systems (2, 4, 35, 38, 68) , the transdominant mutant of Rev, Rev M10, has been used as a model to develop intracellular immunization for AIDS. Genetic strategies which target Rev (1, 16) appear to be attractive since its biological function is required for HIV replication. When the levels of Rev within a cell exceed a certain threshold level, the virus switches from the early nonproductive to the late productive phase of replication (49) . Treatments which maintain Rev below the threshold level should therefore reduce the generation of infectious virus from the cell.
Recombinant viruses have traditionally been used for introducing the inhibitory genes into PBMC. Although reasonably efficient, this gene delivery method has several potential disadvantages. The possibility of infectious virus particles remaining in the sample below the detection level cannot be ruled out, raising potential safety concerns (23, 72) . Gene expression regulated from viral LTRs is often not optimal in PBMC. Such viral vectors generally also lack tissue-regulated gene expression (52) . To overcome these problems, we sought to optimize regulated gene expression. Effective transfer of such vectors into PBMC can be attained either by retroviral vectors (9, 51) or by particle-mediated transfer, as reported previously (70) .
The vector pBL(CD4)-CAT was previously shown to direct gene expression specifically in CD4-positive T cells in transgenic mice (30, 56) . The combination of a 339-bp CD4-specific enhancer element and the CD4 promoter in this vector is a relatively weak activator of gene expression but can maintain lineage-specific expression during development (30, 57) . We were able to increase the transcriptional activity of the CD4 promoter in this vector by adding several heterologous elements. The activity of each of these modified enhancers was compared with that of the original vector as well as the HIVand RSV LTRs. Addition of the TAR sequence of the HIV LTR to the CD4 promoter made the latter responsive to Tat. As reported previously (35) , this element can increase expression of the inhibitory gene from this promoter in response to Tat synthesized after endogenous HIV gene expression and may provide a TAR decoy effect at lower concentrations of Tat (35, 63) . Further addition of a CMV IE enhancer element upstream of the CD4 enhancer element, however, improved the gene expression 100-fold or more in several cell lines ( Fig.  3 and 4) and PBMC (Fig. 5) . The CMV IE enhancer is a strong transcriptional activator with ubiquitous gene expression properties (6) . The CMV IE enhancer consists of binding sites for several cellular transcription factors, including NF-B and Ap1, both of which are inducible by mitogenic or antigenic activation (20, 32, 54) . The presence of such inducible regulatory elements in the vector could provide an advantage by FIG. 6 . Primer extension analysis of pK7cI-Rev M10 transcriptional initiation site. PBMC freshly isolated from a volunteer were stimulated with the immobilized OKT3 antibody for 4 days in AIM-V medium (Gibco BRL). The cells were transduced with pK7cI-Rev M10 vector by particle-mediated gene transfer as described previously (70) . The cells were incubated for an additional 24 h in the presence of human IL-2 (50 U/ml) and harvested, and the total RNA was extracted with Trizol reagent (Gibco BRL); 20 (lanes 1 and 3) or 5 (lanes 2 and 4) g of RNA extracted from untransduced (lanes 1 and 2) or transduced (lanes 3 and 4) cells was used in the assay. An oligonucleotide of 17 bp complementary to the TAR sequence (bp 52 to 68) was end labeled and used in primer extension analysis (53) . The extension product was resolved on a 12% acrylamide gel with 8 M urea. . Cells were harvested 48 h after incubation, and CAT expression levels were determined in the cell lysates. CAT expression in the absence of the Rev expression vector was used as a negative control. The conversion levels, which are usually 40 to 50 times lower in the absence of Rev, were subtracted as the background. In this experiment, the levels of percent conversion induced by pRSV-CAT-RRE were 0.6 and 34.4 in the absence and presence of Rev, respectively. These experiments were repeated at least three times under different conditions, and the data of a representative experiment are shown. Schematic diagrams of the Rev M10 and ⌬Rev M10 expression vectors are shown in Fig. 8 .
allowing increased production of the inhibitory protein in mitogenic or antigen-activated cells. The continuous presence of HIV antigens or immune/inflammatory cytokines in the circulation of HIV-seropositive subjects is likely to stimulate the PBMC, thereby activating cellular transcription factors which stimulate CMV enhancer function, increasing expression of Rev M10; however, the presence of the CMV enhancer in this plasmid also resulted in gene expression in other lineages (Fig.  4) . Such expression is not problematic for application in current gene therapy protocols, since CD4 ϩ cells are preselected prior to gene transfer. It is anticipated that the inclusion of CD4 regulatory elements will be beneficial by maintaining long-term gene expression in vivo, as in transgenic mice (30) , while viral regulatory elements increase expression and optimize the viral infection.
Addition of introns has been shown to enhance the transcriptional activity of the expression vectors and also stabilize the mRNA (8, 27) . Previous reports (11) and preliminary work in our laboratory demonstrated that intron A of the CMV IE gene is a strong transcriptional activator. A search to identify binding motifs for cellular factors within this region revealed no such sequences other than NF-1. Deletion of a large internal sequence, spanning from XcmI to HpaI sites, did not alter the transcription-enhancing activity of this intron, although the deletion removed the NF-1 binding motif. To enhance the transcription activity of the CD4-TAR hybrid promoters, the 386-bp subfragment of CMV IE intron A was added to these expression vectors. This addition resulted in a stronger and prolonged expression of CAT by pK7cI-CAT vector compared to pK7c-CAT, pRSV-TAR-CAT, or HIV-CAT (Fig. 5) .
The CD4 promoter in pK7c-CAT exhibited strong transcriptional activity in PBMC, which was 4.0-and 3.4-fold greater than those of HIV-CAT and RSV-CAT, respectively (Fig. 5) .
Tat transactivation increased this activity an additional 5.8-fold. The parental vector under the same conditions showed no detectable activity. The changes in the parental vector thus rendered it at least 2 logs more active in PBMC. The magnitude of Tat inducibility of the optimized vector, pK7cI, is not as striking as that of the predecessor, pK7c (Fig. 5B ). An inverse relationship between the strength of the promoter and levels of Tat transactivation has been reported previously, largely because the denominator has been increased when calculating fold transactivation; however, TAR is still functional (Fig. 5B) , and similar maximal levels are attained in the presence of Tat with cellular activation. Our previous studies suggest that higher basal levels of Rev M10 allow more effective inhibition of wild-type Rev, and the addition of TAR not only results in inducible gene expression but also functions as an RNA decoy (35) . The data presented in Fig. 7 indicate that, especially at low levels of vector, pK7cI inhibits Rev function better than RSV-TAR in the presence or absence of Tat, confirming that CD4-CMV cassette has the advantage of improved potency for inhibition of Rev function. Most relevant to the antiviral strategy, expression of Rev M10 from CD4-TAR hybrid vectors was found to efficiently block wild-type Rev function. In an in vitro competition assay, Rev M10 strongly inhibited Rev-dependent CAT expression (Fig. 7) . Expression of Rev M10 in PBMC also inhibited the significant reduction in the levels of CAT expression after viral challenge (Fig. 8) . These data indicate that pK7cI can also function in acute viral infection. The potential advantages of the optimized vector, pK7cI, over RSV-TAR are inferred from this assay and the in vitro studies; however, further studies in patients will be needed to address issues of potential clinical efficacy. This study, nevertheless, shows that specific features of HIV replication and cellular gene expression can be exploited to develop potentially more effective genetic interventions for AIDS. The protective effects of this strategy could be attributed to at least three properties of the promoter. Rev M10 is believed to retain the RRE binding property; however, it is defective in Rev multimerization, a process that is critical for recruiting cellular factors to promote viral mRNA transport (37) . The TAR sequence present in the promoter could enhance the basal levels of transcription a few-fold, thereby synthesizing more Rev M10. The TAR motif, on the other hand, may also sequester the available levels of Tat within the cell, thereby indirectly suppressing Tat transactivation of the HIV LTR. Such combinations of antiviral genes and appropriate regulatory elements may optimize the effects of gene products which may inhibit HIV replication and contribute to gene therapy for AIDS.
